Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2024

Open Access 01-12-2024 | COVID-19 | Research

Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction

Authors: Zhipeng Wu, Nan Geng, Zhao Liu, Wen Pan, Yueke Zhu, Jing Shan, Hongbo Shi, Ying Han, Yingmin Ma, Bo Liu

Published in: Virology Journal | Issue 1/2024

Login to get access

Abstract

Background

There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking.

Methods

A total of 226 COVID-19 patients admitted to Beijing Youan Hospital’s emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed.

Results

A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737–0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis.

Conclusion

Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Mertoglu C, et al. COVID-19 is more dangerous for older people and its severity is increasing: a case-control study. Med Gas Res. 2022;12(2):51–4.PubMedCrossRef
4.
Rubin EJ, et al. Audio interview: viral evolution and the future of monoclonal antibodies. N Engl J Med. 2022;386(24):e75.PubMedCrossRef
5.
Xavier Becerra X, Jha A. Project NextGen — defeating SARS-CoV-2 and Preparing. N Engl J Med. 2023;389:773–5.PubMedCrossRef
6.
The L. The COVID-19 pandemic in 2023: far from over. Lancet. 2023;401(10371):79.CrossRef
7.
Kurban LAS, et al. Predicting severe disease and critical illness on initial diagnosis of COVID-19: simple triage tools. Front Med (Lausanne). 2022;9:817549.PubMedCrossRef
8.
Song H, et al. Electrolyte imbalances as poor prognostic markers in COVID-19: a systemic review and meta-analysis. J Endocrinol Invest. 2023;46(2):235–59.PubMedCrossRef
9.
10.
Tjendra Y, et al. Predicting Disease Severity and Outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144(12):1465–74.PubMedCrossRef
11.
Xue G et al. Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19. Int Immunopharmacol, 2020. 89.
12.
Mertoglu C, et al. How do routine laboratory tests change in coronavirus disease 2019? Scand J Clin Lab Invest. 2021;81(1):24–33.PubMedCrossRef
13.
14.
Tahir Huyut M, et al. What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality? Int Immunopharmacol. 2022;105:108542.PubMedPubMedCentralCrossRef
15.
Huyut MT, Ilkbahar F. The effectiveness of blood routine parameters and some biomarkers as a potential diagnostic tool in the diagnosis and prognosis of Covid-19 disease. Int Immunopharmacol. 2021;98:107838.PubMedPubMedCentralCrossRef
16.
Matono T, et al. Diagnostic accuracy of quick SOFA score and inflammatory biomarkers for predicting community-onset bacteremia. Sci Rep. 2022;12(1):11121.PubMedPubMedCentralCrossRef
17.
Bradley J, et al. Pneumonia Severity Index and CURB-65 score are good predictors of mortality in hospitalized patients with SARS-CoV-2 Community-Acquired Pneumonia. Chest. 2022;161(4):927–36.PubMedCrossRef
18.
Bradley P et al. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. BMJ Open Respir Res, 2020. 7(1).
19.
De Socio GV, et al. National early warning score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study. Infection. 2021;49(5):1033–8.PubMedPubMedCentralCrossRef
20.
Schirinzi A et al. New insights in Laboratory Testing for COVID-19 patients: looking for the Role and Predictive Value of Human epididymis secretory protein 4 (HE4) and the Innate immunity of the oral cavity and respiratory tract. Microorganisms, 2020. 8(11).
21.
22.
Memar MY, Baghi HB. Presepsin: a promising biomarker for the detection of bacterial infections. Biomed Pharmacother. 2019;111:649–56.PubMedCrossRef
23.
Chenevier-Gobeaux C, et al. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta. 2015;450:97–103.PubMedCrossRef
24.
25.
Guarino M, et al. Presepsin levels and COVID-19 severity: a systematic review and meta-analysis. Clin Exp Med. 2023;23(4):993–1002.PubMedCrossRef
26.
27.
Asai N, et al. Efficacy and accuracy of qSOFA and SOFA scores as prognostic tools for community-acquired and healthcare-associated pneumonia. Int J Infect Dis. 2019;84:89–96.PubMedCrossRef
28.
Gershengorn HB, et al. Predictive value of sequential organ failure Assessment score across patients with and without COVID-19 infection. Ann Am Thorac Soc. 2022;19(5):790–8.PubMedPubMedCentralCrossRef
29.
Gulec T, et al. Can we recognize severe community-acquired pneumonia without pneumonia severity index? Use of modified qSOFA with procalcitonin. Heliyon. 2023;9(9):e19937.PubMedPubMedCentralCrossRef
30.
Lim WS, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–82.PubMedPubMedCentralCrossRef
31.
32.
Berastegui-Cabrera J, et al. Prepandemic viral community-acquired pneumonia: diagnostic sensitivity and specificity of nasopharyngeal swabs and performance of clinical severity scores. J Med Virol. 2023;95(1):e28317.PubMedCrossRef
33.
Liang W, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081–9.PubMedCrossRef
34.
Wang C, et al. Early predictive value of Presepsin for secondary Sepsis and mortality in Intensive Care Unit patients with severe Acute Pancreatitis. Shock. 2023;59(4):560–8.PubMedCrossRef
35.
Park JE et al. Complementary use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk patients with suspected Sepsis. Biomedicines, 2021. 9(9).
36.
37.
38.
39.
Chang Y, et al. Presepsin predicts severity and secondary bacterial infection in COVID-19 by Bioinformatics Analysis. Comput Math Methods Med. 2022;2022:p9914927.CrossRef
40.
Kim SW, et al. Usefulness of monocyte distribution width and presepsin for early assessment of disease severity in COVID-19 patients. Med (Baltim). 2022;101(27):e29592.CrossRef
41.
Fukada A, et al. Presepsin as a predictive biomarker of severity in COVID-19: a case series. J Med Virol. 2021;93(1):99–101.PubMedCrossRef
42.
Dell’Aquila P, et al. A simple prognostic score based on troponin and presepsin for COVID-19 patients admitted to the emergency department: a single-center pilot study. Acta Biomed. 2021;92(4):e2021233.PubMedPubMedCentral
43.
Assal HH, et al. Presepsin as a Novel Biomarker in predicting In-hospital mortality in patients with COVID-19 pneumonia. Int J Infect Dis. 2022;118:155–63.PubMedPubMedCentralCrossRef
44.
45.
Satici C, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis. 2020;98:84–9.PubMedPubMedCentralCrossRef
46.
Fan G et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J, 2020. 56(3).
47.
Rudd KE, et al. Association of the Quick Sequential (Sepsis-Related) organ failure Assessment (qSOFA) score with excess hospital mortality in adults with suspected infection in low- and Middle-Income Countries. JAMA. 2018;319(21):2202–11.PubMedPubMedCentralCrossRef
48.
Ruangsomboon O, et al. The utility of the Rapid Emergency Medicine Score (REMS) compared with three other early warning scores in predicting in-hospital mortality among COVID-19 patients in the emergency department: a multicenter validation study. BMC Emerg Med. 2023;23(1):45.PubMedPubMedCentralCrossRef
49.
Brajkovic M et al. The Predictive Value of Risk Factors and Prognostic Scores in Hospitalized COVID-19 Patients Diagnostics (Basel), 2023. 13(16).
50.
51.
Huyut MT, Velichko A. Diagnosis and prognosis of COVID-19 Disease using routine blood values and LogNNet neural network. Sens (Basel), 2022. 22(13).
52.
Velichko A et al. Machine learning sensors for diagnosis of COVID-19 Disease using routine blood values for internet of things application. Sens (Basel), 2022. 22(20).
53.
Huyut MT, Huyut Z. Effect of ferritin, INR, and D-dimer immunological parameters levels as predictors of COVID-19 mortality: a strong prediction with the decision trees. Heliyon. 2023;9(3):e14015.PubMedPubMedCentralCrossRef
54.
Chi L, et al. Predictive value of C-reactive protein for disease severity and survival in COVID-19 patients: a systematic review and meta-analysis. Clin Exp Med. 2023;23(6):2001–8.PubMedCrossRef
55.
56.
57.
Acedera ML, et al. Age, comorbidities, c-reactive protein and procalcitonin as predictors of severity in confirmed COVID-19 patients in the Philippines. Heliyon. 2023;9(4):e15233.PubMedPubMedCentralCrossRef
58.
59.
Sayah W, et al. Interleukin-6, procalcitonin and neutrophil-to-lymphocyte ratio: potential immune-inflammatory parameters to identify severe and fatal forms of COVID-19. Cytokine. 2021;141:155428.PubMedPubMedCentralCrossRef
60.
61.
Zavalaga-Zegarra HJ et al. C-Reactive protein-to-albumin ratio and clinical outcomes in COVID-19 patients: a systematic review and Meta-analysis. Trop Med Infect Dis, 2022. 7(8).
62.
Erdogan A, Can FE, Gonullu H. Evaluation of the prognostic role of NLR, LMR, PLR, and LCR ratio in COVID-19 patients. J Med Virol. 2021;93(9):5555–9.PubMedPubMedCentralCrossRef
63.
Zhang JN, et al. Lymphocyte-C-reactive protein ratio can differentiate disease severity of COVID-19 patients and serve as an assistant screening tool for hospital and ICU admission. Front Immunol. 2022;13:957407.PubMedPubMedCentralCrossRef
64.
65.
66.
Behnes M, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014;18(5):507.PubMedPubMedCentralCrossRef
Metadata
Title
Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction
Authors
Zhipeng Wu
Nan Geng
Zhao Liu
Wen Pan
Yueke Zhu
Jing Shan
Hongbo Shi
Ying Han
Yingmin Ma
Bo Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2024
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-024-02367-1

Other articles of this Issue 1/2024

Virology Journal 1/2024 Go to the issue

Research

Antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023

Research

Recognizing the role of Epstein-Barr virus in gastric cancer: transcriptomic insights into malignancy modulation

Methodology

Development of a time-resolved fluorescence immunoassay kit for detecting canine coronavirus and parvovirus through double labeling

Research

RNA-seq analysis of chlorogenic acid intervention in duck embryo fibroblasts infected with duck plague virus

Review

Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development

Research

Pseudorabies virus UL38 attenuates the cGAS-STING signaling pathway by recruiting Tollip to promote STING for autophagy degradation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits